[Guidelines for diagnosis and treatment of glucocorticoid-induced osteoporosis].

J He, F Li, W H Huang, L P Wang, X W Zhang, Y Zhao
{"title":"[Guidelines for diagnosis and treatment of glucocorticoid-induced osteoporosis].","authors":"J He,&nbsp;F Li,&nbsp;W H Huang,&nbsp;L P Wang,&nbsp;X W Zhang,&nbsp;Y Zhao","doi":"10.3760/cma.j.cn112138-20221025-00787","DOIUrl":null,"url":null,"abstract":"<p><p>Glucocorticoid-induced osteoporosis (GIOP) is a skeletal disease characterized by decreased bone strength and increased fracture risk associated with long-term glucocorticoid use. GIOP is the most common secondary osteoporosis that critically affects the quality of life of patients. Currently, the incidence of GIOP in China remains high, with insufficient awareness and lack of prevention and treatment norms. Therefore, the Chinese Rheumatology Association has established this standard based on domestic and international experience, with the aim of raising awareness of prevention and treatment among clinicians, guiding the standardized diagnosis and treatment of this disease, and improving the overall prognosis of patients with GIOP.</p>","PeriodicalId":24000,"journal":{"name":"Zhonghua nei ke za zhi","volume":"62 6","pages":"631-638"},"PeriodicalIF":0.0000,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Zhonghua nei ke za zhi","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3760/cma.j.cn112138-20221025-00787","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Glucocorticoid-induced osteoporosis (GIOP) is a skeletal disease characterized by decreased bone strength and increased fracture risk associated with long-term glucocorticoid use. GIOP is the most common secondary osteoporosis that critically affects the quality of life of patients. Currently, the incidence of GIOP in China remains high, with insufficient awareness and lack of prevention and treatment norms. Therefore, the Chinese Rheumatology Association has established this standard based on domestic and international experience, with the aim of raising awareness of prevention and treatment among clinicians, guiding the standardized diagnosis and treatment of this disease, and improving the overall prognosis of patients with GIOP.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
【糖皮质激素所致骨质疏松症诊疗指南】。
糖皮质激素诱导的骨质疏松症(GIOP)是一种骨骼疾病,其特征是长期使用糖皮质激素导致骨强度下降和骨折风险增加。GIOP是最常见的继发性骨质疏松症,严重影响患者的生活质量。目前,GIOP在中国的发病率仍然很高,但认识不足,缺乏预防和治疗规范。为此,中国风湿病学会结合国内外经验,制定了本标准,旨在提高临床医生的防治意识,指导该病的规范化诊断和治疗,改善GIOP患者的整体预后。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
[Clinical characteristics of sudden sensorineural hearing loss with acute cerebral infarction]. [Recommendations for the diagnosis and treatment of gout in China]. [The interaction between phage and intestinal flora and related research progress in inflammatory bowel disease]. [Multiple intracranial tuberculomas: a case report]. [CT texture analysis for predicting pseudoprogression in metastatic clear cell renal cell carcinoma during PD-1 inhibitor therapy].
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1